CS
FTH

Credit Suisse’s Faeth Therapeutics FTH Stock Holding History

Credit Suisse’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 4265
2022
Q2 		$0 Buy
+1
New +$37 ﹤0.01% 4281

Other funds holding FTH

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse's FTH Position: Q3 2022 in Review

Credit Suisse sold out of Faeth Therapeutics (FTH) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in FTH in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 30 funds tracked by Wall St. Rank hold FTH as of Q3 2022.

  • Credit Suisse reported no remaining Faeth Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 1 Faeth Therapeutics share in Q3 2022.
  • Credit Suisse first reported a position in Faeth Therapeutics in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Faeth Therapeutics position peaked at $0 in Q2 2022.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.